Eplontersen,Inotersen
Ionis Pharmaceuticals,Akcea Therapeutics,Astrazeneca
['astrazeneca', '$ions', 'ionis ', 'medicines company']
ionis today announced at aan 2023 that the phase 3 neuro-ttransform study for astrazeneca and ionis eplontersen in attrv-pn met all co-primary endpoints and secondary endpoints at 66 weeks $ions 